FRVO Investors Have Opportunity to Lead Fervo Energy Company Securities Fraud Lawsuit with SBS Law

FRVO Investors Have Opportunity to Lead Fervo Energy Company Securities Fraud Lawsuit with SBS Law 

LOS ANGELES–(BUSINESS WIRE)–Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fervo Energy Company (“Fervo” or “the Company”) (NASDAQ: FRVO) for violations of the federal securities laws.

Shareholders who purchased shares of FRVO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD: Pursuant and/or traceable to the Company’s May 13, 2026 initial public offering (“IPO”).

DEADLINE: January 18, 2027

If you are a shareholder who suffered a loss, click here to participate.

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Fervo’s pilot plant suffered from premature thermal decline. The Company’s EGS operations experienced injected water loss at levels exceeding the requirements of its commercial plans. The Company’s drilling costs were not declining despite its previous representations. The Company lacked sufficient transmission capacity to deliver power to customers in California. Based on these facts, the Company’s public statements were false and materially misleading throughout the IPO period. When the market learned the truth about Fervo, investors suffered damages.

We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

Join the case to recover your losses

WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Schall, Brown & Schwartz LLP
Brian Schall, Esq.,
Andrew Brown, Esq.,
David Schwartz, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Logo
Logo

ServiceNow (NOW) Faces Investor Scrutiny Amid cRPO Questions, $41 Billion Market Capitalization Gone – HBSS

SAN FRANCISCO, Nov. 21, 2026 (GLOBE NEWSWIRE) — Investors in ServiceNow (NYSE: NOW) saw the price of their shares crater $40.46 (27%) on October 29, 2026 in the wake of the company’s Q3 2026 financial results and guidance. The drop wiped out about over $41 billion of the company’s market capitalization in a single day.

The developments have prompted national shareholders rights firm Hagens Berman open an investigation into whether ServiceNow has been sufficiently transparent about its revenue metrics, including its current revenue performance obligations (“cRPOs”).

The firm urges investors with substantial losses to submit their trading information. The firm also encourages persons with knowledge who may assist the investigation to contact its attorneys.

ServiceNow (NOW) Investigation:

ServiceNow delivers solutions that help organizations govern, secure and manage artificial intelligence and digitalize and streamline workflows to drive collaboration, productivity and better experiences across the enterprise. Its core solution is the ServiceNow AI Platform.

cRPO is one of the company’s key business metrics and indicates contracted revenue ServiceNow expects to recognize during the next 12 months. Throughout 2026, until October 28, during the front end of ServiceNow’s earnings calls management repeatedly touted cRPO growth exceeding prior guidance.

Among other matters, a major focus of the investigation is on the propriety of those beats.

Questions arose during the company’s October 28, 2026 Q3 2026 earnings call. That day, ServiceNow revealed some concerning information. First, it revealed that it obtained early renewals in Q3 that significantly contributed to its slight beat on cRPO guidance. Second, CFO Gina Mastantuono informed investors that the company expected Q4 cRPO growth to be just 18.5%, down from 21% in Q3. Third, in response to analysts’ numerous questions on the topic, she revealed that the renewals have “a negative impact in Q4 because we pulled those deals out of Q4 and into Q3[.]”

The market’s October 29 reaction was brutal, with shares plummeting 27%.

“We’re focused on whether ServiceNow may have misled investors about the value of its widely-touted cRPO growth metric and whether it may have been improperly manipulated,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.

If you invested in ServiceNow and have substantial losses, or have knowledge that will assist the firm’s investigation, submit your losses now »

Whistleblowers: Persons with non-public information regarding ServiceNow should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Contact: Hagens Berman, Reed Kathrein, 715 Hearst Avenue, Suite 300, Berkeley, CA 94710, 844-916-0895, [email protected]



FMC Investors Have Opportunity to Lead FMC Corporation Securities Fraud Lawsuit with SBS Law

FMC Investors Have Opportunity to Lead FMC Corporation Securities Fraud Lawsuit with SBS Law 

LOS ANGELES–(BUSINESS WIRE)–Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against FMC Corporation (“FMC” or “the Company”) (NYSE: FMC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholders who purchased shares of FMC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD: February 4, 2026 to October 14, 2026

DEADLINE: January 19, 2027

If you are a shareholder who suffered a loss, click here to participate.

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. FMC misled investors about the challenges distributors faced in selling high-priced inventory. These sales headwinds impacted the Company’s ability to generate new sales. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about FMC, investors suffered damages.

We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

Join the case to recover your losses.

WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Schall, Brown & Schwartz LLP
Brian Schall, Esq.,
Andrew Brown, Esq.,
David Schwartz, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Logo
Logo

VistaPrint Partners with Acclaimed Restaurateurs Sohla and Ham El-Waylly for Opening of Brooklyn’s Triangle Bar

VistaPrint Partners with Acclaimed Restaurateurs Sohla and Ham El-Waylly for Opening of Brooklyn’s Triangle Bar

From custom deli paper to coasters and menus, VistaPrint is helping bring Fort Greene’s newest neighborhood bar to life

BROOKLYN, N.Y.–(BUSINESS WIRE)–VistaPrint, the print and design partner to millions of small businesses, today announced a partnership with award-winning chefs and culinary personalities, Sohla and Ham El-Waylly, to support Ham’s newest venture with his partners, Anoop Pillarisetti and Michael Tuiach, Triangle Bar.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120304334/en/

VistaPrint Partners with Acclaimed Restaurateurs Sohla and Ham El-Waylly for Opening of Brooklyn’s Triangle Bar

VistaPrint Partners with Acclaimed Restaurateurs Sohla and Ham El-Waylly for Opening of Brooklyn’s Triangle Bar

Located at the base of Fort Greene’s iconic triangular Fowler Square and opening in winter 2026–27, Triangle Bar is reimagining the classic neighborhood bar as a welcoming, all-occasion gathering place for guests to settle in over a pint, enjoy a comforting dinner, or linger over drinks with friends. The bar sits alongside the group’s Brooklyn restaurant, Strange Delight, a critically acclaimed, New Orleans-inspired seafood restaurant and cocktail bar in Fort Greene.

Sohla and Ham partnered with VistaPrint early in the planning process to create a consistent look and feel across every customer-facing touchpoint, including custom-printed sandwich deli paper, signature coasters, menus, takeout packaging and branded signage, t-shirts and hats.

“So much hard work goes into building a small business. Using custom print products is essential when you’re trying to build an identity people remember, and we wanted every detail at Triangle Bar to feel intentional,” said Sohla and Ham El-Waylly. “When we opened Strange Delight, coordinating orders across multiple vendors while maintaining quality was exhausting. Having VistaPrint as our one-stop shop for all things branding completely streamlined the process. We’re so excited to share Triangle Bar with the Fort Greene community.”

The partnership reflects VistaPrint’s ongoing commitment to championing food and beverage entrepreneurs by providing cohesive, high-quality marketing that turn brands into community destinations from opening day and beyond.

“Sohla and Ham are two of the culinary world’s most trusted voices, embodying the creativity and resilience required to build something completely their own,” said Heather Deschenes, Vice President, North America Marketing at VistaPrint. “Food and beverage branding and marketing live in tangible details that guests interact with every day. By serving as an end-to-end partner for Triangle Bar, VistaPrint makes it easy for entrepreneurs to bring their vision to life.”

For more information about the partnership and to explore the products used for the opening of Triangle Bar, click here.

About VistaPrint

VistaPrint is the print and design partner to millions of small businesses and households around the world. We help small business owners bring their ideas to life through custom print products, easy-to-use digital tools and expert design support. VistaPrint is a Cimpress company (Nasdaq: CMPR).

Ryan Roccaforte

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Office Products Marketing Communications Specialty Professional Services Small Business Restaurant/Bar Food/Beverage Retail Online Retail

MEDIA:

Photo
Photo
VistaPrint Partners with Acclaimed Restaurateurs Sohla and Ham El-Waylly for Opening of Brooklyn’s Triangle Bar
Photo
Photo
Photo
Photo
Photo
Photo
Photo
Photo
Photo
Photo
Photo
Photo
Logo
Logo

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against FMC Corporation (FMC)

NEW YORK, Nov. 20, 2026 (GLOBE NEWSWIRE) — Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of Pennsylvania on behalf of all persons or entities who purchased or otherwise acquired FMC Corporation (“FMC” or the “Company”) (NYSE: FMC) securities between February 4, 2026, to October 14, 2026, inclusive (the “Class Period”). The class action charges FMC and certain of FMC’s top executives with violations of the Exchange Act.

The Complaint alleges that Defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of FMC’s distributor-inventory problem, including the extent to which elevated-priced inventory held by distributors was difficult to sell thereby impairing replenishment orders across FMC’s portfolio and threatening the Company’s ability to generate new sales, revenue, EBITDA and cash flow.

The Complaint also alleges that the truth emerged after the market closed on October 14, 2026 when FMC announced preliminary third quarter 2026 results materially below expectations and sharply reduced its revenue and adjusted EBITDA for the quarter.

The Complaint further alleges that investors and analysts reacted immediately to FMC’s revelation. The Complaint continues to allege that the price of FMC’s common stock declined from a closing market price of $8.09 per share on October 14, 2026, FMC’s stock price fell to $5.62 per share on October 15, 2026, a decline of about 31%.
        
Investors who purchased or otherwise acquired shares of FMC should contact the Firm prior to the January 19, 2027 lead plaintiff motion deadline. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].

Please visit our website at http://www.gme-law.com for more information about the firm.



Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy

  • Company receives Complete Response Letter from FDA for Deramiocel BLA
  • Conference call and webcast Monday, November 23, at 8:30 a.m. ET

SAN DIEGO, Nov. 20, 2026 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its resubmitted Biologics License Application (BLA) for Deramiocel, its investigational cell therapy for Duchenne muscular dystrophy (DMD). The CRL states that the FDA does not consider the data sufficient to establish substantial evidence of effectiveness and cites certain other clinical deficiencies.

“We are deeply disappointed for the boys and young men living with Duchenne and their families,” said Linda Marbán, Ph.D., Capricor’s Chief Executive Officer. “Deramiocel has been studied in two randomized, double-blind, placebo-controlled trials, HOPE-2 and HOPE-3, both of which met their primary endpoints. We stand behind the rigor of our clinical program and the integrity of our data, and we believe the data support approval. We are reviewing the letter carefully and will share next steps once we have completed our evaluation.”

As of September 30, 2026, the Company had cash, cash equivalents, restricted cash and marketable securities of approximately $198.5 million, which it believes is sufficient to fund its planned operations for at least the next 12 months. The Company is reviewing its operating costs to further extend its cash runway.

Conference Call and Webcast

To participate in the conference call, please dial 1-800-717-1738 (Domestic) or 1-646-307-1865 (International) and reference the conference ID: 27699. Participants may dial in using the numbers above and ask to be joined to the call or click the Call Me™ link for instant telephone access to the event. To participate via a webcast, please click here. A replay of the webcast will be available shortly after the conclusion of the live event and will be accessible in the Investors section of the Company’s website.

About Duchenne Muscular Dystrophy

Duchenne muscular dystrophy (DMD) is a severe, X-linked genetic disorder characterized by progressive muscle degeneration affecting the skeletal, respiratory, and cardiac muscles. It is caused by the absence of functional dystrophin, a key structural protein in muscle cells. DMD affects approximately 15,000 individuals in the United States, primarily males. Over time, deterioration of the heart muscle leads to cardiomyopathy and heart failure, the leading cause of death in DMD. There is no cure, and treatment options remain limited.

About Deramiocel

Deramiocel (CAP-1002) consists of allogeneic cardiosphere-derived cells (CDCs), a rare population of cardiac cells that have been shown in preclinical and clinical studies to exert immunomodulatory and anti-fibrotic actions in the preservation of skeletal and cardiac muscle function in muscular dystrophies such as DMD. CDCs act by secreting extracellular vesicles known as exosomes, which target macrophages and alter their expression profile to adopt a healing rather than pro-inflammatory phenotype. For the treatment of DMD, Deramiocel holds Orphan Drug, RMAT and Rare Pediatric Disease designations in the U.S., and Orphan Drug and ATMP designations in Europe.

About Capricor Therapeutics

Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing cell and exosome-based therapeutics for the treatment of rare diseases. Our lead product candidate, Deramiocel, is an allogeneic cardiac-derived cell therapy in late-stage development for the treatment of Duchenne muscular dystrophy, evaluated in clinical studies for its potential to preserve skeletal and cardiac muscle function. Capricor is also advancing its proprietary StealthX™ exosome platform for the targeted delivery of oligonucleotides, proteins, and small-molecule therapeutics across a range of diseases. At Capricor, we are committed to delivering new therapies for patients with rare diseases. For more information, visit capricor.com and follow Capricor on Facebook, Instagram and X.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the initiation, conduct, size, timing and results of clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including future interactions with regulatory authorities and the ability to obtain regulatory approvals or otherwise bring products to market; the contents of, and our response to, the Complete Response Letter and the timing of any resubmission; manufacturing capabilities; dates for regulatory meetings; the potential that required regulatory inspections may be delayed or not be successful, which would delay or prevent product approval; revenue and reimbursement estimates; projected terms of definitive agreements, our financial position, cash runway and planned cost reductions, our possible uses of existing cash and investment resources; results of securities litigation; and statements regarding our litigation with Nippon Shinyaku Co., Ltd. and NS Pharma, Inc., including the nature of the dispute, our expectations regarding any legal proceedings, and our ability to commercialize Deramiocel independent of our existing distribution agreement; and any other statements about Capricor’s management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor’s business is set forth in Capricor’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the Securities and Exchange Commission on March 17, 2026, and in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, as filed with the Securities and Exchange Commission on November 10, 2026. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.

Deramiocel and Capricor’s StealthX™ exosome therapeutics are investigational and have not been approved for commercial use in any indication.

For more information, please contact:

Capricor Media Contact:

Caitlin Kasunich / Raquel Cona
KCSA Strategic Communications
[email protected] / [email protected]
212.896.1241 / 516.779.2630

Capricor Company Contact:

AJ Bergmann, Chief Financial Officer
[email protected]
858.727.1755



Honeywell Aerospace 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Honeywell Aerospace, Inc. – HONA

Honeywell Aerospace 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Honeywell Aerospace, Inc. – HONA

NEW YORK & NEW ORLEANS–(BUSINESS WIRE)–Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until November 23, 2026 to file lead plaintiff applications in a securities class action lawsuit against Honeywell Aerospace, Inc. (“Honeywell” or the “Company”) (NasdaqGS: HONA), if they purchased or otherwise acquired the Company’s shares between June 29, 2026 and September 1, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Arizona.

What You May Do

If you purchased shares of Honeywell as above and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-833-538-3615 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-hona/ to learn more. If you wish to serve as a lead plaintiff in this class action by overseeing lead counsel with the goal of obtaining a fair and just resolution, you must request this position by application to the Court by November 23, 2026.

About the Lawsuit

According to the Complaint, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects.

Specifically, the lawsuit alleges that Defendants failed to disclose to investors that: (i) a small percentage of the Company’s suppliers had a “disproportionate impact” on sales; (ii) those suppliers were suffering supply constraints; (iii) the foregoing was reasonably likely to have a material unfavorable impact on sales and profitability; (iv) the Company was under investigation for potential violations of the False Claims Act for failing to comply with cybersecurity requirements for government contracts; and (v) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

The case is Green v. Honeywell Aerospace, Inc., et al., No. 26-cv-06779.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms – According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-833-538-3615
1100 Poydras St., Suite 960
New Orleans, LA 70163

KEYWORDS: Louisiana New York United States North America

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Logo
Logo

MEDIROM Regains Compliance with Nasdaq’s Periodic Filing Requirement

TOKYO, Nov. 20, 2026 (GLOBE NEWSWIRE) — MEDIROM Healthcare Technologies Inc. (Nasdaq: MRM) (the “Company”) today announced that it received written notice dated November 20, 2026, from Nasdaq Listing Qualifications confirming that the Company has regained compliance with the periodic filing requirement under Nasdaq Listing Rule 5250(c)(1), because the Company filed its Form 20-F for the year ended December 31, 2025 on November 18, 2026. Accordingly, Nasdaq has closed the matter relating to the delayed filing of the Company’s annual report.

The Company remains subject to the previously disclosed minimum bid price deficiency under Nasdaq Listing Rule 5550(a)(2) and has until April 5, 2027 to regain compliance with that requirement. Nasdaq’s confirmation regarding the periodic filing requirement does not resolve this separate deficiency.

About MEDIROM Group
MEDIROM Group operates approximately 281 wellness salons under the “Re.Ra.Ku®” brand nationwide. Since 2015, we have expanded into HealthTech, offering on-demand training apps like Lav® for specific health guidance and lifestyle improvement programs. In 2020, we started manufacturing the 24/7 recharge-free smart tracker “MOTHER Bracelet®,” which is now used in REMONY, our remote monitoring system for various industries including caregiving, transportation, construction, and manufacturing.

About MEDIROM Healthcare Technologies Inc.

NASDAQ Symbol: MRM
Tradepia Odaiba, 2-3-1 Daiba, Minato-ku, Tokyo, Japan
Website: https://medirom.co.jp/en
Contact: [email protected]



Advanced Micro Devices, Inc. Investigated on Behalf of Investors with $100,000 or More in Losses – Contact the DJS Law Group to Discuss Your Rights – AMD

Advanced Micro Devices, Inc. Investigated on Behalf of Investors with $100,000 or More in Losses – Contact the DJS Law Group to Discuss Your Rights – AMD

LOS ANGELES–(BUSINESS WIRE)–The DJS Law Group announces that it is investigating claims on behalf of investors of Advanced Micro Devices, Inc. (“AMD” or “the Company”) (NASDAQ: AMD) for violations of the securities laws.

INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. AMD is the subject of a research report issued by Hunterbrook Media on November 19, 2026. According to the report, “after the U.S. blacklisted Chinese server maker IEIT Systems, the company kept getting newer AMD firmware, which enables AMD chips to run in servers.” The report also alleges that the Company “bills over 20% of its revenue to customers in China and Hong Kong,” and “depends on a Chinese partner to finish most of its chips.” Based on this news, shares of AMD fell by more than 7.7% on the same day.

If you are a shareholder who suffered a loss, contact us to participate.

WHY DJS LAW GROUP? DJS Law Group’s primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Surgery Partners, Inc. Announces Expiration and Results of Consent Solicitation Relating to Surgery Center Holdings, Inc.’s 7.250% Senior Notes due 2032

BRENTWOOD, Tenn., Nov. 20, 2026 (GLOBE NEWSWIRE) — Surgery Partners, Inc. (“Surgery Partners”) (Nasdaq: SGRY) announced today the results of the previously announced solicitation of consents (the “Consent Solicitation”) by its indirect wholly owned subsidiary, Surgery Center Holdings, Inc. (the “Issuer”), from holders (“Holders”) of its outstanding $1,225,000,000 aggregate principal amount of 7.250% Senior Notes due 2032 (CUSIP Nos. 86881W AF9 / U86786 AD9 / U86786 AE7; ISINs US86881WAF95 / USU86786AD98 / USU86786AE71) (the “Notes”) to certain proposed amendments (the “Proposed Amendments”) to the indenture governing the Notes, dated as of April 10, 2024 (as supplemented, the “Indenture”), among the Issuer, the guarantors party thereto and Wilmington Trust, National Association, as trustee (the “Trustee”). The Consent Solicitation was made upon the terms and subject to the conditions set forth in the Issuer’s Consent Solicitation Statement, dated November 16, 2026 (as amended by Amendment No. 1 thereto, dated November 16, 2026, and Amendment No. 2 thereto, dated November 18, 2026, the “Consent Solicitation Statement”).

The Consent Solicitation expired at 5:00 p.m., New York City time, on November 20, 2026 (the “Expiration Time”). As of the Expiration Time, according to information provided by S&P Global Inc., the information and tabulation agent for the Consent Solicitation, the Issuer had received the requisite consents with respect to the Notes (the “Requisite Consents”) to effect the Proposed Amendments.

As previously announced, on October 23, 2026, Surgery Partners entered into an Agreement and Plan of Merger (as amended by Amendment No. 1 thereto, dated as of November 8, 2026, and as it may be further amended, supplemented or otherwise modified from time to time, the “Merger Agreement”) with Spyglass Topco, LLC (“Topco”), Spyglass Merger Subsidiary, Inc., a wholly owned subsidiary of Topco (“Merger Sub”), and, solely for the limited purposes set forth therein, Bon Secours Mercy Health, Inc. (“BSMH”). Pursuant to the Merger Agreement, Merger Sub will merge with and into Surgery Partners, with Surgery Partners surviving as a wholly owned subsidiary of Topco (the “Merger”).

The Proposed Amendments will amend the Indenture to (i) provide that, concurrently with and following the consummation of the Merger in accordance with the terms of the Merger Agreement on or prior to the date that is five business days after the End Date (as defined in the Merger Agreement), each of BSMH, HealthSpan Partners, a 501(c)(3) Ohio corporation affiliated with BSMH, and their respective affiliates, and certain groups of which any of them are members, will be “Permitted Holders” under the Indenture, in addition to the existing Permitted Holders, and (ii) add to, amend, supplement or change certain other defined terms in the Indenture related to the foregoing. Except for the Proposed Amendments, all existing terms of the Notes and the Indenture will remain unchanged, and the Proposed Amendments will not alter the Issuer’s obligation to pay the principal of or interest on the Notes or the stated interest rate or maturity date of the Notes.

The Issuer intends to execute a supplemental indenture to the Indenture setting forth the Proposed Amendments (the “Supplemental Indenture”) on or around November 24, 2026. The Supplemental Indenture will become effective upon its execution and delivery, but the Proposed Amendments will become operative only immediately prior to the consummation of the Merger, provided that the Consent Fee has been paid. Once operative, the Proposed Amendments will be binding on all Holders, including those that did not deliver consents. If the Consent Fee is paid but the Merger is not consummated on or prior to the date that is five business days after the End Date, the Proposed Amendments will not become operative, and Holders that received the Consent Fee will retain it.

Holders who validly delivered (and did not validly revoke) consents prior to the Expiration Time will receive a cash payment equal to $5.00 per $1,000 in principal amount of Notes for which such consents were delivered (the “Consent Fee”). The Issuer expects to pay the Consent Fee on November 24, 2026, whether or not the Merger is consummated.

Jefferies LLC acted as solicitation agent and S&P Global Inc. acted as information and tabulation agent in connection with the Consent Solicitation. Questions regarding the Consent Solicitation may be directed to Jefferies LLC at (212) 284-2368 (collect) or to S&P Global Inc. at (212) 849-3880 (banks and brokers) or (888) 593-9546 (toll-free), or by email at [email protected].

This press release is for informational purposes only and does not constitute an offer to purchase or a solicitation of an offer to sell the Notes or any other securities and does not constitute a solicitation of consents with respect to the Notes or any other securities. The Consent Solicitation was made only by, and pursuant to the terms of, the Consent Solicitation Statement, and the information in this press release is qualified in its entirety by reference to the Consent Solicitation Statement.

About Surgery Partners

Surgery Partners is a leading healthcare services company with a differentiated outpatient delivery model focused on providing high quality, cost effective solutions for surgical and related ancillary care in support of both patients and physicians. Founded in 2004, Surgery Partners is one of the largest and fastest growing surgical services businesses in the country, with more than 200 locations in 30 states, including ambulatory surgery centers, surgical hospitals, multi-specialty physician practices and urgent care facilities.

Additional Information and Where to Find It

In connection with the proposed acquisition by an affiliate of BSMH of the Company (the “Transactions”), the Company will file with the Securities and Exchange Commission (the “SEC”) a proxy statement (the “Proxy Statement”), a definitive version of which will be mailed or otherwise provided to its stockholders. The Company and certain other filing persons intend to jointly file a transaction statement on Schedule 13E-3 (the “Schedule 13E-3”). The Company may also file other documents with the SEC regarding the proposed Transactions. BEFORE MAKING ANY VOTING DECISION, THE COMPANY’S STOCKHOLDERS ARE URGED TO CAREFULLY READ THE PROXY STATEMENT AND THE SCHEDULE 13E-3 IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE AND ANY OTHER DOCUMENTS FILED WITH THE SEC AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS THERETO IN CONNECTION WITH THE PROPOSED TRANSACTIONS OR INCORPORATED BY REFERENCE THEREIN BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTIONS AND THE PARTIES TO THE PROPOSED TRANSACTIONS. Investors and security holders may obtain free copies of the Proxy Statement, the Schedule 13E-3 and other documents that the Company files with the SEC (when available) from the SEC’s website at www.sec.gov and the Company’s website at ir.surgerypartners.com. In addition, the Proxy Statement, the Schedule 13E-3 and other documents filed by the Company with the SEC (when available) may be obtained from the Company free of charge by directing a request to the Company’s Investor Relations at [email protected].

Participants in the Solicitation

The Company and certain of its directors, executive officers and employees may be deemed to be participants in the solicitation of proxies from the Company’s stockholders in connection with the proposed Transactions. Information regarding the persons who may, under the rules of the SEC, be deemed to be participants in the solicitation of the stockholders of the Company in connection with the proposed Transactions, including a description of their respective direct or indirect interests, by security holdings or otherwise will be set forth in the Proxy Statement and Schedule 13E-3 and other materials to be filed with the SEC. You may also find additional information about the Company’s directors and executive officers in the Company’s proxy statement for its 2026 Annual Meeting of Stockholders, which was filed with the SEC on April 23, 2026 (the “Annual Meeting Proxy Statement”) , including under the sections entitled “Security Ownership of Certain Beneficial Owners and Management”, “Proposal No. 1 Election of Directors”, and “Executive Officers” therein. To the extent holdings of securities by potential participants (or the identity of such participants) have changed since the information printed in the Annual Meeting Proxy Statement, such information has been or will be reflected in the Company’s Statements of Change in Ownership on Forms 4 filed with the SEC. The Company’s stockholders may obtain additional information regarding the direct and indirect interests of the participants in the solicitation of proxies in connection with the proposed Transactions, including the interests of the Company’s directors and executive officers in the proposed Transactions, which may be different than those of the Company’s stockholders generally, by reading the Proxy Statement and Schedule 13E-3 and other relevant materials to be filed with the SEC relating to the proposed Transactions. You can obtain free copies of these documents from the Company using the contact information above.

No Offer

No person has commenced soliciting proxies in connection with the proposed Transactions referenced in this communication, and this communication is neither an offer to purchase nor a solicitation of an offer to sell securities, nor a solicitation of any vote or approval.

Cautionary Note Regarding Forward-Looking Statements

This communication contains forward-looking statements. Forward-looking statements generally relate to future events, the Company’s future financial or operating performance or the proposed Transactions. All statements other than statements of historical facts contained in this communication, including statements regarding the proposed Transactions, the Consent Fee, the Proposed Amendments and their expected timing, completion and effects, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,” “likely,” “may,” “might,” “should,” “plans,” “potential,” “projects,” “will,” or the negative of these words or other similar terms or expressions that concern the Company’s expectations, strategy, plans or intentions.

Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual future events or results due to a variety of factors. Important factors that could cause actual outcomes or results to differ materially from the forward-looking statements include, but are not limited to, (a) the ability of the parties to consummate the proposed Transactions in a timely manner or at all; (b) the satisfaction (or waiver) of closing conditions to the consummation of the proposed Transactions; (c) the potential impact of the unsolicited proposal from a third party or possibility that more competing offers may be made; (d) potential delays in consummating the proposed Transactions; (e) the timing, receipt and terms and conditions of any required governmental and regulatory approvals of the proposed Transactions that could delay the consummation of the proposed Transactions or cause the parties to abandon the proposed Transactions; (f) the possibility that the Company may not receive the requisite stockholder approval for the proposed Transactions; (g) the ability of the Company to timely and successfully achieve the anticipated benefits of the proposed Transactions; (h) the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the merger agreement with BSMH; (i) the Company’s ability to implement its business strategy; (j) significant transaction costs associated with the proposed Transactions, as well as liabilities that are not known, probable or estimable at this time or other unexpected costs, charges or expenses; (k) the possibility that the proposed Transactions may be more expensive to complete than anticipated, including as a result of unexpected factors or events; (l) potential litigation relating to the proposed Transactions; (m) the risk that disruptions from the proposed Transactions will harm the Company’s business, including current plans and operations; (n) risks related to the diversion of management’s time and attention from the Company’s ongoing business operations to matters relating to the proposed Transactions; (o) the ability of the Company to retain and hire key personnel; (p) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed Transactions; (q) legislative, regulatory and economic developments affecting the Company’s business; (r) general economic and market developments and conditions; (s) the legal, regulatory and tax regimes under which the Company operates; (t) potential business uncertainty, including changes to existing business relationships, during the pendency of the proposed Transactions that could affect the Company’s financial performance; (u) the risk that any announcements relating to the proposed Transactions or the unsolicited proposal from a third party could have adverse effects on the market price of the Company’s common stock, and the risk that such price may decline significantly if the proposed Transactions are not consummated on the anticipated timeline, or at all; (v) restrictions during the pendency of the proposed Transactions that may impact the Company’s ability to pursue certain business opportunities or strategic transactions; and (w) unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism or outbreak of war or hostilities, as well as the Company’s response to any of the aforementioned factors. There can be no assurance that the proposed Transactions will in fact be consummated. The foregoing list of factors is not exhaustive, and new risks may emerge from time to time. It is not possible for the Company to predict all risks, nor can the Company assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement.

For information regarding other factors that could cause the Company’s results to vary from expectations, please see the “Risk Factors” section of the Company’s periodic report filings with the SEC, including but not limited to the Company’s Form 10-Q filed with the SEC on November 9, 2026 and the Company’s Form 10-K filed with the SEC on March 2, 2026, as well as other documents that may be filed by the Company from time to time with the SEC. These filings, as well as subsequent filings, are available on the investor relations section of the Company’s website at ir.surgerypartners.com or on the SEC’s website at www.sec.gov. The statements in this communication represent the Company’s current beliefs, estimates and assumptions as of the date of this communication. Subsequent events and developments may cause the Company’s views to change. Except as required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this communication.

Contacts

Surgery Partners Investor Relations
+1 (615) 234-8940
[email protected]

Dan Scorpio / Jim Polson
FTI Consulting
+1 (872) 344-5356 / +1 (312) 375-5908
[email protected] / [email protected]